PLK1 and its role in the evolving landscape of KRAS-mutated colorectal cancer

被引：1
|
作者：
Harvey, Harry [1 ]
Chen, Eric Xueyu [1 ]
机构：
[1] Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, 7-824,700 Univ Ave, Toronto, ON M5G 1Z5, Canada
来源：
JOURNAL OF GASTROINTESTINAL ONCOLOGY | 2024年 / 15卷 / 04期
关键词：
Kirsten rat sarcoma virus (KRAS); colorectal cancer (CRC); targeted therapy; RAS; INHIBITOR; FOLFIRI; BEVACIZUMAB; GEMCITABINE; COMBINATION; ISIS-2503;
D O I：
10.21037/jgo-24-323
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1987 / 1992
页数：6
相关论文
共 50 条
  • [1] The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers
    Tria, Simon Manuel
    Burge, Matthew E.
    Whitehall, Vicki L. J.
    CANCERS, 2023, 15 (08)
  • [2] PLK1 expression and KRAS mutations in colorectal cancer
    Jayachandran, P.
    Elliott, A.
    Battaglin, F.
    Lou, E.
    Zhang, W.
    Soni, S.
    Arai, H.
    Wang, J.
    Millstein, J.
    Lockhart, A. C.
    Korn, W. M.
    Lenz, H. J.
    ANNALS OF ONCOLOGY, 2020, 31 : S442 - S442
  • [3] Sotorasib in KRAS-Mutated Colorectal Cancer
    Fojo, Tito
    Fakih, Marwan G.
    Chao, Joseph
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (02): : 186 - 187
  • [4] Unravelling the role of PLK1 in tumorigenesis by revealing the mutational landscape of colorectal and lung cancer with PLK1 mutations
    Wang, Shuo
    Gao, Feng
    Bi, Yinghui
    Zhao, Xiaotian
    Ou, Qiuxiang
    Zhu, Minyi
    Wu, Xue
    Zhang, Xuefei
    Mao, Kaiping
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2024, 28 (12)
  • [5] Microenvironment targets in KRAS-mutated metastatic colorectal cancer
    Marchio, Serena
    Bartolini, Alice
    Cardaci, Sabrina
    Soster, Marco
    Corti, Giorgio
    Lamba, Simona
    Bussolino, Federico
    Cora', Davide
    Nicolantonio, Federica D.
    CANCER RESEARCH, 2014, 74 (19)
  • [6] MicroRNA signature associated with KRAS-mutated colorectal cancer
    Andreoiu, O-M
    Dobre, M.
    Pirvu, I-R
    Vasilescu, F.
    Herlea, V.
    Becheanu, G.
    VIRCHOWS ARCHIV, 2017, 471 : S161 - S162
  • [7] Novel modalities in the treatment of patients with KRAS-mutated colorectal cancer
    Dimou, Anastasios
    Syrigos, Konstantinos
    Saif, Muhammad Wasif
    ANTI-CANCER DRUGS, 2011, 22 (05) : 384 - 391
  • [8] Advanced therapies on BRAF-mutated and KRAS-mutated metastatic colorectal cancer
    LI Zi-nan
    YU Li-feng
    WANG Jia-qi
    NIU Yan-xin
    WANG Xin-yu
    ZHAO Lin
    中国药理学与毒理学杂志, 2019, (10) : 883 - 883
  • [9] Clinical Role of ASCT2 (SLC1A5) in KRAS-Mutated Colorectal Cancer
    Toda, Kosuke
    Nishikawa, Gen
    Iwamoto, Masayoshi
    Itatani, Yoshiro
    Takahashi, Ryo
    Sakai, Yoshiharu
    Kawada, Kenji
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (08)
  • [10] Phase Ib/II study of the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with FOLFIRI and bevacizumab for second line treatment of KRAS-mutated metastatic colorectal cancer
    Ahn, D. H.
    Erlander, M.
    Ridinger, M.
    Samuelsz, E.
    Barzi, A.
    Bekaii-Saab, T.
    Lenz, H. J.
    ANNALS OF ONCOLOGY, 2020, 31 : S427 - S427
12345